Recent Study: Algeria Pharmaceuticals & Healthcare Report Q4 2012

New Healthcare research report from Business Monitor International is now available from Fast Market Research

by Bill Thompson

(WireNews+Co) - Boston, MA - 26 October 2012

BMI View: Algeria will remain of interest to multinational pharmaceutical companies intent on reaching out to emerging markets. However, the country's full potential will not be reached until the regulatory environment strengthens. Despite its substantial potential rewards, underpinned by a growing population and the changing disease profile, Algeria remains the riskiest markets in its immediate region.

Headline Expenditure Projections:

- Pharmaceuticals: DZD218.52bn (US$3.00bn) in 2011 to DZD239.44bn (US$3.19bn) in 2012; +9.6% in local currency terms and +6.5% in US dollar terms. Forecast up marginally from Q312 on account of analyst intervention.
- Healthcare: DZD530.66bn (US$7.28bn) in 2011 to DZD585.52bn (US$7.81bn) in 2012; +10.3% in local currency terms and +7.2% in US dollar terms. Forecast up marginally from Q312 on the back of new historic data.
- Medical devices: DZD28.26bn (US$388mn) in 2011 to DZD30.83bn (US$411mn) in 2012; +9.1% in local currency terms and +6.0% in US dollar terms. Forecast up marginally from Q312 due to new imports data.

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/464472_algeria_pharmaceuticals_healthcare_report_q4_2012.aspx) (http://www.fastmr.com/prod/464472_algeria_pharmaceuticals_healthcare_report_q4_2012.asp)

Risk/Reward Rating: In Q412, Algeria retains its composite score of 46.6 out of the maximum 100 points. However, the country slipped from 12th to 14th position among the 30 regional markets surveyed in the Middle East and Africa (MEA) region due to improvements in the scores of other countries. Despite above-average rewards opportunities, Algeria continues to be viewed as a very risky market, with this quarter's score for overall risks remaining at just 34 out of 100.

Key Trends And Developments:

- In April 2012, the Algerian Pharmacovigilance Centre deputy director, Professor Lumi, said that 2,500-3,000 cases of side-effects were recorded at the centre in 2011, far less than should be expected if all clinicians were reporting all adverse drug reactions (ADRs). Another pharmacist at the Pierre et Marie Curie Centre said that side-effects cannot be adequately dealt with if clinicians do not report them. The centre depends on health professionals to provide information about side-effects to ensure improved assessment and monitoring. However, cultural and traditional reluctance exists to reporting side effects, which is compounded by the lack of resources.
- Algeria has been successful in attracting foreign direct investment (FDI) in pharmaceuticals. FDI in medicine increased to US$364mn in the last two years in Algeria, reported the Algerian Press Service in April, citing Djamel Ould Abbes, the minister of health, population and hospital reform. Abbes said the FDI has facilitated the introduction of various programmes between domestic and foreign laboratories.

Fast Market Research (http://www.fastmr.com) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.